A Registry to Assess Long-Term Safety of Patients With B-Lymphocyte Malignancies Treated With Tisagenlecleucel in South Korea
Status: Recruiting
Location: See all (12) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 100
Healthy Volunteers: f
View:
• Patients who receive tisagenlecleucel infusion in the commercial setting, treated under a managed access program or other pathway, e.g., when product was manufactured for the commercial setting but turned out to be out of specification (OOS).
• Consented to data collection.
Locations
Other Locations
Republic of Korea
Novartis Investigative Site
RECRUITING
Bundang Gu
Novartis Investigative Site
RECRUITING
Busan
Novartis Investigative Site
RECRUITING
Gyeonggi-do
Novartis Investigative Site
RECRUITING
Incheon
Novartis Investigative Site
RECRUITING
Seongnam-si
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2025-03-12
Estimated Completion Date: 2039-12-30
Participants
Target number of participants: 179
Treatments
Tisagenlecleucel
Patients who have been treated with tisagenlecleucel
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals